Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details

Q: How long will it take to read this news story?

The story "Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details" has 330 words across 17 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details" was covered 9 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 300 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22875802</li><li>URL: https://beamstart.com/news/shilpa-medicare-shares-rise-3-17280183013168</li></ul>

Business Standard Logo Business Standard 9h ago

Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details - Business Standard

Quick Summary:

The company also offers contract research and manufacturing services to various clients.

This CEP showcases our proficiency in quality-oriented development as well as commercial manufacturing capabilities that meet the expectations of global quality standards paving way for more such products to follow.

With unwavering commitment and belief in our technical capabilities, we have invested in developing a versatile peptide portfolio over the past few years and Desmopressin is the first peptide molecule to receive CEP from the European Regulators.